Abstract
The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 391-394 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 20 |
| Issue number | 1 A |
| State | Published - 2000 |
| Externally published | Yes |
Fingerprint
Keywords
- Angiogenesis
- Batismatat metalloproteinase inhibitor
- Interleukin 12
- Melanoma
- Mice
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. / Dabrowska, Anna; Giermasz, Adam; Marczak, Maria; Gołab, Jakub; Jakóbisiak, Marek.
In: Anticancer Research, Vol. 20, No. 1 A, 2000, p. 391-394.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice
AU - Dabrowska, Anna
AU - Giermasz, Adam
AU - Marczak, Maria
AU - Gołab, Jakub
AU - Jakóbisiak, Marek
PY - 2000
Y1 - 2000
N2 - The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
AB - The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
KW - Angiogenesis
KW - Batismatat metalloproteinase inhibitor
KW - Interleukin 12
KW - Melanoma
KW - Mice
UR - http://www.scopus.com/inward/record.url?scp=0034070283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034070283&partnerID=8YFLogxK
M3 - Article
C2 - 10769685
AN - SCOPUS:0034070283
VL - 20
SP - 391
EP - 394
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 1 A
ER -